PMID- 37335082 OWN - NLM STAT- MEDLINE DCOM- 20230707 LR - 20230809 IS - 1945-4589 (Electronic) IS - 1945-4589 (Linking) VI - 15 IP - 12 DP - 2023 Jun 16 TI - hucMSCs treatment prevents pulmonary fibrosis by reducing circANKRD42-YAP1-mediated mechanical stiffness. PG - 5514-5534 LID - 10.18632/aging.204805 [doi] AB - Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial pneumonia of unknown cause. The most typical characteristic of IPF is gradual weakening of pulmonary elasticity and increase in hardness/rigidity with aging. This study aims to identify a novel treatment approach for IPF and explore mechanism of mechanical stiffness underlying human umbilical cord mesenchymal stem cells (hucMSCs) therapy. Target ability of hucMSCs was examined by labeling with cell membrane dye Dil. Anti-pulmonary fibrosis effect of hucMSCs therapy by reducing mechanical stiffness was evaluated by lung function analysis and MicroCT imaging system and atomic force microscope in vivo and in vitro. Results showed that stiff environment of fibrogenesis caused cells to establish a mechanical connection between cytoplasm and nucleus, initiating expression of related mechanical genes such as Myo1c and F-actin. HucMSCs treatment blocked force transmission and reduced mechanical force. For further exploration of mechanism, ATGGAG was mutated to CTTGCG (the binding site of miR-136-5p) in the full-length sequence of circANKRD42. Wildtype and mutant plasmids of circANKRD42 were packaged into adenovirus vectors and sprayed into lungs of mice. Mechanistic dissection revealed that hucMSCs treatment repressed circANKRD42 reverse splicing biogenesis by inhibiting hnRNP L, which in turn promoted miR-136-5p binds to 3'-Untranslated Region (3'-UTR) of YAP1 mRNA directly, thus inhibiting translation of YAP1 and reducing YAP1 protein entering nucleus. The condition repressed expression of related mechanical genes to block force transmission and reduce mechanical forces. The mechanosensing mechanism mediated directly by circANKRD42-YAP1 axis in hucMSCs treatment, which has potential general applicability in IPF treatment. FAU - Zhang, Haitong AU - Zhang H AD - Department of Respiratory and Critical Care Medicine, Binzhou Medical University Hospital, Binzhou Medical University, Binzhou 256603, China. FAU - Zhu, Qi AU - Zhu Q AD - Department of Cellular and Genetic Medicine, School of Pharmaceutical Sciences, Binzhou Medical University, Yantai 264003, China. FAU - Ji, Yunxia AU - Ji Y AD - Department of Respiratory and Critical Care Medicine, Binzhou Medical University Hospital, Binzhou Medical University, Binzhou 256603, China. FAU - Wang, Meirong AU - Wang M AD - Department of Cellular and Genetic Medicine, School of Pharmaceutical Sciences, Binzhou Medical University, Yantai 264003, China. FAU - Zhang, Qian AU - Zhang Q AD - Department of Pathology, Binzhou Medical University Hospital, Binzhou Medical University, Binzhou 256603, China. FAU - Liu, Weili AU - Liu W AD - Department of Respiratory and Critical Care Medicine, Binzhou Medical University Hospital, Binzhou Medical University, Binzhou 256603, China. FAU - Li, Ruiqiong AU - Li R AD - Department of Clinical Nursing, Binzhou Medical University Hospital, Binzhou Medical University, Binzhou 256603, China. FAU - Zhang, Jinjin AU - Zhang J AD - Department of Cellular and Genetic Medicine, School of Pharmaceutical Sciences, Binzhou Medical University, Yantai 264003, China. FAU - Xu, Pan AU - Xu P AD - Department of Respiratory and Critical Care Medicine, Binzhou Medical University Hospital, Binzhou Medical University, Binzhou 256603, China. FAU - Song, Xiaodong AU - Song X AD - Department of Cellular and Genetic Medicine, School of Pharmaceutical Sciences, Binzhou Medical University, Yantai 264003, China. FAU - Lv, Changjun AU - Lv C AD - Department of Respiratory and Critical Care Medicine, Binzhou Medical University Hospital, Binzhou Medical University, Binzhou 256603, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230616 PL - United States TA - Aging (Albany NY) JT - Aging JID - 101508617 RN - 0 (MicroRNAs) RN - 0 (MIRN136 microRNA, human) RN - 0 (Myo1c protein, mouse) RN - EC 3.6.1.- (Myosin Type I) SB - IM MH - Humans MH - Mice MH - Animals MH - *Idiopathic Pulmonary Fibrosis/metabolism MH - Fibrosis MH - Lung/pathology MH - *MicroRNAs/metabolism MH - *Mesenchymal Stem Cells/metabolism MH - Myosin Type I/metabolism PMC - PMC10333056 OTO - NOTNLM OT - YAP1 OT - circRNA OT - hucMSCs OT - mechanical stiffness OT - pulmonary fibrosis COIS- CONFLICTS OF INTEREST: The authors declare no conflicts of interest related to this study. EDAT- 2023/06/19 13:08 MHDA- 2023/07/07 06:42 PMCR- 2023/06/30 CRDT- 2023/06/19 08:53 PHST- 2022/12/29 00:00 [received] PHST- 2023/05/23 00:00 [accepted] PHST- 2023/07/07 06:42 [medline] PHST- 2023/06/19 13:08 [pubmed] PHST- 2023/06/19 08:53 [entrez] PHST- 2023/06/30 00:00 [pmc-release] AID - 204805 [pii] AID - 10.18632/aging.204805 [doi] PST - ppublish SO - Aging (Albany NY). 2023 Jun 16;15(12):5514-5534. doi: 10.18632/aging.204805. Epub 2023 Jun 16.